

Datasheet

SARS-CoV-2 full-length Trimeric Spike Recombinant Antigen B.1.617 Mutation (Indian Variant)

Catalogue No:	BSV-COV-PR-92	BSV-COV-PR-94	BSV-COV-PR-95
Pack Size:	100 µg	1 mg	10 mg
Product Name:	SARS-CoV-2 full-length Trimeric Spike Recombinant Antigen B.1.617 Mutation (Indian Variant)		
WHO Reference:	G/452R.V3		
Description:	Spike protein of the mutant strain B.1.617, also commonly known as the "Indian Variant". It is a full-length protein, which is active in its native trimeric form, that is stabilized in LMNG detergent.		
Alternative Name:	SPIKE_SARS2 Spike glycoprotein		
UniProt No:	P0DTC2		
Protein Class:	Single span transmembrane protein		
Organism:	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)		
Sequence:	Full-length sequence (aa 1 – 1273), G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H,		
	furin cleavage site "RRAR" mutated to "GSAG"; K986P, V987P		
Host:	Expressed in HEK293 Expi cells		
Size (Trimeric):	3 x 142 kDa = 426 kDa		
Buffer:	20 mM Hepes pH 7.5; 150 mM NaCl, 0.001% LMNG		
Form:	Liquid		
Function:	Host cell surface receptor binding; fusion of virus membrane with host endosome membrane		

Would you like to receive further information?
Please contact:





Activity:	Not Determined		
Applications:	ELISA assays, Ligand Binding assays, Biochemical & Biophysical analyses		
Shipping:	Dry ice		
Storage:	-80°C. Avoid freeze-thaw cycles.		
Background:	The B.1.617 variant is referred as a 'double mutation' since substitutions L452R & E484Q are caused by mutations in the gene encoding the SARS-CoV-2 spike protein. In countries other than India, the variant has been detected beginning late February in the United Kingdom and United States.		

<u>Disclaimer</u>: Our products are intended for molecular biology applications. These products are not intended for the diagnosis, prevention or treatment of a disease.

Would you like to receive further information?
Please contact:

